$1.150
-0.109 (-9.45%)At close
SBFM News
SBFM Events
Sunshine Biopharma Files to Sell 24.48M Shares of Common Stock
Sunshine Biopharma files to sell 24.48M shares of common stock
Sunshine Biopharma Updates on K1.1 Project Progress
Sunshine Biopharma provided an update and outlined next plans for its oncology project, the K1.1 mRNA lipid nanoparticle program. The gene encoding the K1.1 mRNA is a tumor suppressor that is frequently mutated in a variety of cancers, including hepatocellular carcinoma, non-small cell lung cancer, and pancreatic cancer. Mutations in the gene of K1.1 mRNA create "cold" tumors that evade host immunosurveillance. In NSCLC and pancreatic cancers, a limited set of oncogenes is predominantly associated with mutations in the K1.1 gene, contributing to poor treatment prognosis. "Our results to date have demonstrated that the K1.1 mRNA LNP can be successfully delivered systemically in vivo. K1.1 mRNA has been shown to be well tolerated and capable of restoring expression of the target tumor suppressor in grafted liver tumors in a dose dependent manner. Proof of concept studies further indicated that K1.1 mRNA exhibits tumor suppressing activity in vivo as a single agent in at least two orthotopic HCC mouse models," the company said.
Sunshine Biopharma Receives Approval for Generic Enalapril in Canada
Sunshine Biopharma announces the approval of its generic Enalapril tablets 2.5mg, 5mg, 10mg and 20mg for the Canadian market. Enalapril is the generic equivalent of the brand name, Vasotec.
Sunshine Biopharma Approves 2mg Generic Dienogest for Canada
Sunshine Biopharma announce the approval of its generic Dienogest tablets of 2mg for the Canadian market. Dienogest is the generic equivalent of the brand name, Visanne Dienogest works through progesterone receptor binding, local anti-inflammatory actions, and mild hormone suppression. It reduces endometriosis pain by shrinking abnormal tissue growth.
Sunshine Biopharma Approves Generic Ondansetron Tablets for Canada
Sunshine Biopharma announces the approval of its generic Ondansetron tablets of 4mg and 8mg for the Canadian market. Ondansetron is the generic equivalent of the brand name, Zofran. Sunshine Biopharma has established a distribution network across Canada through its wholly owned Canadian subsidiary, Nora Pharma. The addition of Ondansetron to its portfolio of drugs represents a strategic expansion for the Company into the area of nausea and vomiting caused by cancer therapy. The Company anticipates that its Ondansetron will be ready to ship to pharmacies by the end of 2026.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.